Background Use of the direct oral anticoagulant rivaroxaban has strongly increased in
Europe since its market approval for non-valvular atrial fibrillation in 2011. Patients …

Purpose To evaluate effectiveness and safety of rivaroxaban versus warfarin or dabigatran
etexilate in a prospective cohort of routine care non‐valvular atrial fibrillation (AF) patients …

Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation
treated with rivaroxaban. Methods: Retrospective study in which patients treated with …

Abstract Background The Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation
(XANTUS) registry investigated the safety and efficacy of the factor Xa inhibitor rivaroxaban …

Background Little is known about the utilization of rivaroxaban in real life treatment settings
in France. Aims Objectives of this study were to describe the conditions of use and treatment …

Aims To analyze the clinical profile and management of patients with nonvalvular atrial
fibrillation taking rivaroxaban in routine practice in Spain. Methods Clinical data from the …

Background The Xarelto Post-Authorization Safety and Effectiveness Study in Japanese
Patients with Atrial Fibrillation (XAPASS) was designed to investigate safety and …

Background Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in
determining whether evidence from randomised controlled clinical trials translate into …

Introduction Non-vitamin-K oral anticoagulants (NOACs) were recommended in preference
to oral vitamin K antagonists (VKAs) in the 2020 updated guidelines for stroke prevention in …

Method We used data from the prospective, non-interventional DRESDEN NOAC
REGISTRY to evaluate rates of stroke/transient ischaemic attack (TIA)/systemic embolism …